FDA approves Lupin’s generic Adcirca
Lupin has received the Food and Drug Administration’s blessing for its generic Adcirca (tadalafil) tablets in 20-mg dosage strength.
The product is the generic of Eli Lilly’s branded product. It is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
The product had a market value of roughly $474.3 million, according to December 2018 IQVIA data.
No comments found